Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ADAGRASIB vs ADALIMUMAB-RYVK: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ADAGRASIB vs ADALIMUMAB-RYVK: Safety Overview

Metric ADAGRASIB ADALIMUMAB-RYVK
Total FAERS Reports 899 463
Deaths Reported 315 48
Death Rate 35.0% 10.4%
Hospitalizations 350 112
Average Patient Age 68.3 yrs 50.0 yrs
% Female Patients 56.4% 63.0%
FDA Approval Date Dec 12, 2022 N/A
Manufacturer Mirati Therapeutics, Inc A-S Medication Solutions
Route ORAL SUBCUTANEOUS
Marketing Status Prescription Prescription